Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljaf455 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Mutong Zhao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Key Discipline of Pediatrics, Key Laboratory of Major Di…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Interleukin-4 Receptor alpha Subunit, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Keymed Biosciences (Chengdu) Co., Ltd.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Stapokibart is a novel anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
Objectives
To assess the safety, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of stapokibart in children with moderate-to-severe AD.
Methods
This was a multicentre open-label single-arm phase Ib/IIa trial (NCT06162507) involving 8 weeks of treatment and 8 weeks of follow-up. Children aged 6–11 years received subcutaneous stapokibart based on a bodyweight-tiered regimen (30–60 kg: 300 mg every 3 weeks for a total of three doses, including a 600-mg loading dose; 15–30 kg: 150 mg every 2 weeks for a total of four doses, including a 300-mg loading dose).
Results
Twenty-five patients (13 weighing 30–60 kg; 12 weighing 15–30 kg) received stapokibart; 68% reported mild or moderate adverse events. At week 8, 54% (n = 7/13) of those weighing 30–60 kg and 75% (n = 9/12) of those weighing 15–30 kg achieved a ≥ 75% improvement from baseline in Eczema Area and Severity Index. Stapokibart concentrations increased rapidly following the first dose, climbed further with repeated dosing and gradually declined after treatment discontinuation. Stapokibart reduced inflammatory biomarkers in both groups. No treatment-related antidrug antibodies were detected. No new safety signals emerged.
Conclusions
Stapokibart shows potential in improving disease outcomes and appears to be well tolerated in children aged 6–11 years with moderate-to-severe AD. Larger controlled studies are needed to confirm long-term benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, National Center for Childre…
- Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Department of Dermatology, Hunan Children's Hospital, Changsha, Hunan, China.
- Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China.
- Department of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
- Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, China.
ORCID-Profile: Mutong Zhao, Zhu Wei, Zhimiao Lin, Xu Li, Lin Ma
Förderung
- Keymed Biosciences (Chengdu) Co., Ltd
Zitieren
APA
Zhao, M., Xu, Z., Wu, L., Wei, Z., Yang, B., Lin, Z., Ding, Y., Hu, G., Wang, H., Qian, Q., Ran, Q., Li, X., Xu, Y., Xu, Y., Huang, Y., Jia, Y., Chen, B., & Ma, L. (2026). Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf455
Vancouver
Zhao M, Xu Z, Wu L, Wei Z, Yang B, Lin Z, et al. Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf455
BibTeX
@article{Zhao2026,
author = {Zhao, Mutong and Xu, Zigang and Wu, Liming and Wei, Zhu and Yang, Bin and Lin, Zhimiao and Ding, Yangfeng and Hu, Guohong and Wang, Hua and Qian, Qiufang and Ran, Qin and Li, Xu and Xu, Yayun and Xu, Yufeng and Huang, Yanqiu and Jia, Yingmin and Chen, Bo and Ma, Lin},
title = {Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6–11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljaf455}
}
EUVIMED